CM350 / Keymed Biosciences - LARVOL DELTA

A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=248 | Recruiting | Sponsor: Keymed Biosciences Co.Ltd | N=92 ➔ 248 | Trial completion date: Mar 2025 ➔ Apr 2027 | Trial primary completion date: Mar 2025 ➔ Apr 2027

Enrollment change • Trial completion date • Trial primary completion date • Solid Tumor • GPC3

Keymed Biosciences Announces Annual Results of 2024 (GlobeNewswire) - "CM350 (GPC3 x CD3 bispecific antibody): Continuously proceeded with a Phase I/II clinical study in 2024 to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CM350 in patients with advanced solid tumors. As of the date of this announcement, the product is currently in the dose-escalation of Phase I/II clinical study."

Trial status • Solid Tumor

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 (PRNewswire) - "Keymed Biosciences...announced today that the first patient has been dosed in the Phase I trial of CM350....The phase I trial is being conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of CM350 in patients with solid tumors."

Trial status • Oncology • Solid Tumor

A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=92 | Recruiting | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • GPC3

A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=92 | Not yet recruiting | Sponsor: Keymed Biosciences Co.Ltd

New P1/2 trial • Oncology • Solid Tumor • GPC3